bsm-51222M
[Primary Antibody]
H2AFX (8C5) Monoclonal Antibody
DATASHEET
Host: Mouse
Target Protein: H2AFX
Immunogen Range: 100-143/143
Clonality: Monoclonal
Isotype: IgG1
Entrez Gene: 3014
Swiss Prot: P16104
Source: This H2AFX antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 115-143 amino acids from the C-terminal region of human H2AFX.
Purification: Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Background:
Variant histone H2A which replaces conventional H2A in a subset of nucleosomes. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. Required for checkpoint-mediated arrest of cell cycle progression in response to low doses of ionizing radiation and for efficient repair of DNA double strand breaks (DSBs) specifically when modified by C-terminal phosphorylation.
Size: 100ul
Concentration: 0.5ug/ul
Predicted Molecular Weight: 15
Cross Reactive Species: Human
For research use only. Not intended for diagnostic or therapeutic use.
PRODUCT SPECIFIC PUBLICATIONS
- Jie Hao. et al. Multifunctional miR181a nanoparticles promote highly efficient radiotherapy for rectal cancer. MATER TODAY ADV. 2022 Dec;16:100317Read more>>
- Li, Guang. et al. Synergetic delivery of artesunate and isosorbide 5-mononitrate with reduction-sensitive polymer nanoparticles for ovarian cancer chemotherapy. J NANOBIOTECHNOL. 2022 Dec;20(1):1-13Read more>>
- Lisha Peng. et al. miR-128-3p increases the radiosensitivity in nasopharyngeal carcinoma via regulating vascular endothelial growth factor C. PATHOL RES PRACT. 2023 Aug;:154768Read more>>
VALIDATION IMAGES
Lane 1: 293 Cell lysates; Lane 2: CEM Cell lysates; Lane 3: HepG2 Cell lysates; Lane 4: Jurkat Cell lysates; Lane 5: HeLa Cell lysates; Lane 6: Raji Cell lysates; probed with H2AFX (8C5) Monoclonal Antibody, unconjugated (bsm-51222M) at 1:2000 overnight at 4°C followed by a conjugated secondary antibody for 60 minutes at 37°C.
Paraformaldehyde-fixed, paraffin embedded Human Thymus tissue; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 15 minutes; Blocking buffer (3% BSA) at room temperature for 30min; Antibody incubation with H2AFX (8C5) Monoclonal Antibody (bsm-51222M) at 1:25 for 1 hour at 37°C, followed by a conjugated secondary antibody for 20 minutes and DAB staining.
Paraformaldehyde-fixed, paraffin embedded human prostate tissue; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 15 minutes; Blocking buffer (3% BSA) at room temperature for 30min; Antibody incubation with H2AFX (8C5) Monoclonal Antibody (bsm-51222M) at 1:25 for 1 hour at 37°C, followed by a conjugated secondary antibody for 20 minutes and DAB staining.
Paraformaldehyde-fixed, paraffin embedded Human thymus; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with H2AFX (8C5) Monoclonal Antibody, Unconjugated (bsm-51222M) at 1:50 overnight at 4°C, DAB staining.
Paraformaldehyde-fixed, paraffin embedded Human prostate; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with H2AFX (8C5) Monoclonal Antibody, Unconjugated (bsm-51222M) at 1:25 overnight at 4°C, DAB staining.
Paraformaldehyde-fixed, paraffin embedded Human thymus; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with H2AFX (8C5) Monoclonal Antibody, Unconjugated (bsm-51222M) at 1:25 overnight at 4°C, DAB staining.
Paraformaldehyde-fixed, paraffin embedded Human skin cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with H2AFX (8C5) Monoclonal Antibody, Unconjugated (bsm-51222M) at 1:200 overnight at 4°C, DAB staining.
Paraformaldehyde-fixed, paraffin embedded Human brain; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with H2AFX (8C5) Monoclonal Antibody, Unconjugated (bsm-51222M) at 1:200 overnight at 4°C, DAB staining.
Lane 1: Human MCF-7 cell Lysates; Lane 2: Human 293T cell Lysates; Lane 3: Human Jurkat cell Lysates; Lane 4: Human Hela cell Lysates; Lane 5: Human K562 cell Lysates; Lane 6: Human MOLT4 cell Lysates; Lane 7: Human U2OS cell Lysates. Probed with H2AFX monoclonal Antibody, unconjugated (bsm-51222M) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.
Lane 1: Human MCF-7 cell Lysates; Lane 2: Human 293T cell Lysates; Lane 3: Human Jurkat cell Lysates; Lane 4: Human Hela cell Lysates; Lane 5: Human K562 cell Lysates; Lane 6: Human MOLT4 cell Lysates; Lane 7: Human U2OS cell Lysates. Probed with H2AFX monoclonal Antibody, unconjugated (bsm-51222M) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.